Physician profile
Matthew Bednar
NPI 1528041860
$3,915.96
in general payments reported to CMS, 2019-2025
17 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $336 · 2021: $264 · 2022: $810 · 2023: $543 · 2024: $764 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $510.88 | 2022-2025 | Miebo, Infuse, Xiidra |
| Johnson & Johnson Vision Care, INC. | $439.50 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $386.16 | 2019-2023 | Cequa |
| Allergan, INC. | $381.78 | 2019-2022 | |
| Alcon Vision LLC | $358.74 | 2019-2025 | Hydrus Microstent, Total30, Precision7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $325.55 | 2019-2020 | |
| Glaukos Corporation | $314.14 | 2020-2022 | |
| Oyster Point Pharma, INC. | $286.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $176.82 | 2020-2022 | |
| Sight Sciences, INC. | $148.43 | 2023 | Omni Surgical System |
| Astellas Pharma US INC | $120.87 | 2024 | Izervay |
| Harrow Eye, LLC | $118.35 | 2024 | Vevye |
| Tarsus Pharmaceuticals, INC. | $113.97 | 2024 | Xdemvy |
| Rxsight INC | $91.93 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Abb Con-Cise Optical Group LLC | $75.00 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $53.68 | 2023 | Opd-III |
| Coopervision INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bednar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.